# Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

> **NCT04990739** · PHASE1 · UNKNOWN · sponsor: **MetaboMed Inc** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** MTB-9655

## Key facts

- **NCT ID:** NCT04990739
- **Lead sponsor:** MetaboMed Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04990739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04990739, "Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04990739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*